Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer

NCT06081777 · clinicaltrials.gov ↗
UNKNOWN
Status
65
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Peking University Cancer Hospital & Institute

Collaborators